Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;45(3):e70033.
doi: 10.1002/npr2.70033.

Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan

Affiliations

Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan

Yuji Masataka et al. Neuropsychopharmacol Rep. 2025 Sep.

Abstract

Aim: Cannabis has historically been used for medicinal and industrial purposes, but is strictly regulated worldwide due to the psychoactive effects of THC. In Japan, cannabis is frequently labeled a "gateway drug," yet strong causal evidence for progression to other substances is limited. This study investigates whether cannabis acts as a gateway drug among Japanese users.

Methods: An anonymous online survey was conducted in January 2021 with 3900 individuals reporting lifetime cannabis use in Japan. Participants were recruited via social media. The survey gathered data on demographics, cannabis and other substance use history, order of substance initiation, psychiatric background, and criminal records. A Sankey diagram visualized substance use progression, and odds ratios were calculated to assess the likelihood of using other substances following cannabis use.

Results: Of all respondents, 81.5% were male, with the largest age group being 20-24. Tobacco and alcohol were the most common initial substances, while cannabis was typically the third. Odds for subsequent use of alcohol, tobacco, methamphetamine, and other illicit drugs after cannabis use were 1.25, 0.77, 0.08, and 0.78, respectively, suggesting low probabilities of progression. Nearly half of those who reported cannabis as their third drug did not use other substances afterward.

Conclusion: Cannabis use in Japan typically follows alcohol and tobacco, and rarely leads to further drug use. These findings challenge the gateway hypothesis in the Japanese context. Shared vulnerabilities and strict drug policies may shape these patterns. Further research is warranted to explore the impact of legal changes on drug use behavior.

Registry and registration number of the study/trial: Not applicable.

Keywords: Japan; cannabis; gateway drug hypothesis; marijuana; substance use.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Sankey diagram illustrating the sequential patterns of substance use among community‐based cannabis users in Japan (N = 3900). The diagram displays the progression from the first to the fifth substance used, including cannabis. The width of each flow represents the number of respondents reporting a given transition. Tobacco (48.1%) and alcohol (42.3%) were the most common initial substances, followed by benzodiazepines and cannabis. Cannabis was most frequently used as the third substance (68.2%). Notably, 54.7% of individuals who used cannabis as their third substance reported no further transition to other substances. This visualization highlights that cannabis use in Japan typically follows the use of alcohol and tobacco and does not commonly lead to the use of other substances.

Similar articles

References

    1. Ziyan X., Yaolei M., Lingzhe K., et al., “ Cannabis Sativa: Origin and History, Glandular Trichome Development, and Cannabinoid Biosynthesis,” Horticultural Research 10 (2023): uhad150. - PMC - PubMed
    1. Matthew T., Welling M. A., Deseo A. B., and Monika S. D., “Biosynthetic Origins of Unusual Cannabimimetic Phytocannabinoids in Cannabis Sativa L: A Review,” Phytochemistry 201 (2022): 113282. - PubMed
    1. Vučković S., Srebro D., Vujović K. S., Vučetić Č., and Prostran M., “Cannabinoids and Pain: New Insights From Old Molecules,” Frontiers in Pharmacology 9 (2018): 1259. - PMC - PubMed
    1. Perucca E., “Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?,” Journal of Epilepsy Research 7 (2017): 61–76. - PMC - PubMed
    1. Anil S. M., Peeri H., and Koltai H., “Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action,” Frontiers in Pharmacology 13 (2022): 908198. - PMC - PubMed

LinkOut - more resources